Menu Search
Equities

Zymeworks Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
ZA8:DUS

Zymeworks Inc

Actions
  • Price (EUR)19.20
  • Today's Change0.600 / 3.23%
  • Shares traded500.00
  • 1 Year change+46.56%
  • Beta1.2354
Data delayed at least 15 minutes, as of Feb 12 2026 18:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

  • Revenue in USD (TTM)134.48m
  • Net income in USD-63.43m
  • Incorporated2022
  • Employees263.00
  • Location
    Zymeworks Inc108 Patriot Drive, Suite AMIDDLETOWN 19709United StatesUSA
  • Phone+1 (302) 274-8744
  • Fax+1 (302) 655-5049
  • Websitehttps://www.zymeworks.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.